Addressing Challenges for Patients With Relapsed CLL
Neil E. Kay, MD, a professor of medicine at the Mayo Clinic, discusses the challenges that arise when treating a patient with relapsed chronic lymphocytic leukemia (CLL). Most times, responses in this setting are short lived.
Neil E. Kay, MD, a professor of medicine at the Mayo Clinic, discusses the challenges that arise when treating a patient with relapsed chronic lymphocytic leukemia (CLL). Historically, responses in this setting have been short lived.
Newer drugs such as ibrutinib (Imbruvica), idelalisib (Zydelig), rituximab (Rituxan), and venetoclax (Venclexta) have been approved by the FDA for relapsed/refractory CLL. Kay notes there is less emphasis on prognostic factors to determine whether a patient would be able to receive these agents. However, adverse prognostic factors mean less to a physician when treating a patient with one of these agents, Kay says.
